The Deep Cave Bacteria Defying Modern Medicine
Scientists exploring the isolated Lechuguilla Cave discovered microbial communities that are resistant to virtually all natural antibiotics, despite being sealed off for millions of years. Genomic analysis of a *Paenibacillus* strain revealed dozens of known resistance genes and five entirely novel ones. The study confirms that antibiotic resistance is an ancient, natural phenomenon, not solely a product of modern drug overuse. Researchers now aim to harness these ancient defense mechanisms to inspire new antimicrobial agents and predictive tools against superbugs.
UK Study Reveals No Additional Advantage of Surfactant Therapy in Severe Bronchiolitis Cases in Infants
UK researchers completed the largest randomized trial evaluating exogenous surfactant in infants with severe bronchiolitis requiring mechanical ventilation. The Bronchiolitis Endotracheal Surfactant Study (BESS) enrolled 232 infants across 15 pediatric centers and found that surfactant administration did not shorten ventilation...
Psychedelic Drug MDMA Could Help Treat PTSD—But There's a Reason It's Not Widely Available
Australia became the first nation to reclassify MDMA from a prohibited to a controlled substance, permitting its use in PTSD treatment under strict conditions. The 2026 guidelines limit MDMA‑assisted psychotherapy to adults who have not responded to first‑line therapies, require...
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026
Prothena and its partners presented new clinical data on prasinezumab for Parkinson’s disease and BMS‑986446 for Alzheimer’s disease at the AD/PD 2026 conference in Copenhagen. The PASADENA and PADOVA extensions suggest a two‑year disease‑progression delay and sustained biomarker effects, supporting the...
Metformin vs Dapagliflozin: Heart Protection in Diabetic Rats
Researchers compared metformin and dapagliflozin in diabetic rats subjected to myocardial infarction, finding dapagliflozin delivered stronger cardio‑protective effects. The SGLT2 inhibitor markedly reduced oxidative stress, inflammatory cytokines, and infarct size, while also improving calcium handling and contractile efficiency. Metformin showed...
Indian Pharmaceutical Industry Projected to Reach USD 130 Billion by 2030, Driven by Exports, Policy Push
India’s pharmaceutical sector is projected to expand from a $60 billion domestic market to $130 billion by 2030, according to the Economic Survey 2025‑26. Export revenues surged to $30.5 billion in FY25, a 16‑fold increase since 2000, while the industry now supplies roughly...
Noteworthy Studies on JAK Inhibitors, Skin-Gut Relationship in Alopecia Areata: Maria Hordinsky, MD
Maria Hordinsky, MD highlighted the rapid evolution of alopecia areata therapy, noting three FDA‑approved Janus kinase (JAK) inhibitors launched in the last five years. She discussed the efficacy of agents such as dupilumab and baricitinib, while emphasizing emerging research on...
Aelis Farma Announces the Successful Start of the Recruitment of the Phase 2B Clinical Trial with AEF0217 for the Treatment...
Aelis Farma announced that recruitment has begun for its Phase 2B trial of AEF0217, a first‑in‑class signalling‑specific CB1 receptor inhibitor, aimed at treating behavioral and cognitive impairments in Down syndrome. The study will enroll 188 participants aged 16‑32 across ten...
FDA Drug Safety Communication: Planned Return of CardioGen-82 to Market with New Boxed Warning
On February 15, 2012, the FDA announced that Bracco Diagnostics’ CardioGen‑82 generator will re-enter the U.S. market after a voluntary recall in July 2011. The agency approved revised labeling that introduces a Boxed Warning and new “Alert Limits” for strontium‑82...
FDA Drug Safety Communication: Safety Update on Progressive Multifocal Leukoencephalopathy (PML) Associated with Tysabri (Natalizumab)
The FDA has revised the Tysabri (natalizumab) label to detail progressive multifocal leukoencephalopathy (PML) risk based on infusion count and prior immunosuppressant exposure. Data show 102 PML cases among 82,732 treated patients, with incidence rising sharply after 24 infusions. A...
Researchers Uncover Gut-Liver Serotonin Pathway that Limits Nanoparticle and Viral Delivery
Scientists at the University of Science and Technology of China identified a gut‑liver serotonin signaling axis that governs the rapid clearance of nanomedicines and viral vectors. The pathway links intestinal commensal bacteria to hepatic Kupffer cells, where serotonin amplifies phagocytic...
FDA Approves Nivolumab Regimen as First-Line Treatment for Classical Hodgkin Lymphoma
The FDA has granted first‑line approval for a nivolumab‑plus‑AVD regimen in patients aged 12 and older with stage III‑IV classical Hodgkin lymphoma. The decision follows the phase 3 SWOG S1826 trial, which showed a 58% progression‑free survival rate and a hazard ratio of...
Higher-Dose Semaglutide Approved Under New FDA Accelerated Review Process
The FDA granted accelerated approval to Wegovy HD, a 7.2 mg weekly semaglutide injection, marking the fourth product cleared under the National Priority Voucher pilot. Phase 3 STEP UP data showed a mean 20.7% weight loss, with nearly one‑third of participants shedding 25% or...
Early Use of Tirzepatide After Heart Attack or Stroke Linked to Key Cardiovascular Benefits
A real‑world propensity‑matched study of 1,666 non‑diabetic patients found that initiating tirzepatide within 14 days of an acute myocardial infarction or ischemic stroke cut the risk of emergency‑room visits, hospitalizations, acute kidney injury, repeat stroke and heart‑failure admission over two...
Top HHS Official Tamps Down Expectations on Scope of TrumpRx
The White House’s top drug‑pricing negotiator, Chris Klomp, clarified that the TrumpRx initiative is intended primarily to increase price transparency rather than serve as a broad marketplace for discounted drugs. He emphasized that the program will provide data tools and...
Review Highlights Multiple Treatment Options Available in DLBCL
A new review in Frontiers in Immunology outlines the expanding arsenal against diffuse large B‑cell lymphoma (DLBCL), the most common aggressive non‑Hodgkin lymphoma. While R‑CHOP still achieves durable remission in about 60% of patients, the authors detail how CAR‑T cells,...
Notices of Updates
The FDA released a series of updates between 2020 and 2026 that revise, recognize, or withdraw antimicrobial susceptibility breakpoints and standards for dozens of drugs. Recent actions include recognizing M100 MIC and disk‑diffusion breakpoints for amikacin, cefiderocol, and several beta‑lactam...
In the Clinic for March 20, 2026
The March 20, 2026 "In the Clinic" page aggregates a wide array of BioWorld snapshots, special reports, and infographics covering biopharma, medical technology, and emerging therapeutic areas. It links to daily data snapshots, market outlooks, and deep‑dive analyses such as the med‑tech...
Generic Semaglutide Versions Roll Out at Prices Pegged 80% Less that Novo Nordisk’s Ozempic
Indian drugmakers Natco Pharma, Glenmark Pharmaceuticals and Eris Lifesciences are set to launch generic semaglutide on March 23, 2026, just after the drug’s patent expired. The generics are priced roughly 80% less than Novo Nordisk’s Ozempic, with Natco’s vials costing...
Earendil Labs to Scale AI-Driven Biologics Platform with $787 Million Funding
Earendil Labs announced a $787 million financing round, the largest recent capital raise for AI‑enabled drug development. The funding, led by Sanofi and the Biotech Development Fund, will be used to scale its AI‑driven biologics discovery platform, expand R&D teams, and...
UK’s NICE Revisits Lilly, Eisai Alzheimer's Drugs Under New Pricing Threshold
The UK’s National Institute for Health and Care Excellence (NICE) has reopened its evaluation of Eli Lilly’s donanemab and Eisai’s lecanemab after initially rejecting them on cost grounds. A newly‑introduced cost‑effectiveness threshold of roughly £20,000 per quality‑adjusted life year (QALY)...
Orthogonal Tri‐Modular Coiled‐Coil Assembly for Programmable Multi‐Cargo Display on Escherichia Coli Nissle 1917
Researchers have engineered a tri‑specific scaffold cell (TriSC) platform in the probiotic strain *Escherichia coli* Nissle 1917 that uses three orthogonal coiled‑coil motifs to create a programmable, reversible surface. The system enables simultaneous, selective attachment of multiple nanobody cargos and...
Roche Ends Run for Muscular Atrophy Drug, Leaving Door Open for Competitors
Roche announced it will discontinue development of its anti‑myostatin antibody emugrobart for spinal muscular atrophy (SMA) after the Phase 2/3 MANATEE trial failed to demonstrate consistent muscle‑growth or motor‑function benefits. The study enrolled 259 patients and compared emugrobart plus Evrysdi against...
Rhythm Obesity Drug Wins Broader Use From FDA
The FDA approved Rhythm Pharmaceuticals' once‑daily injection Imcivree for acquired hypothalamic obesity in adults and children aged four and up. Clinical trials showed an 18‑percentage‑point weight‑loss advantage over placebo, making it the first therapy for this rare, brain‑injury‑driven condition. Rhythm...
Genentech Culls Muscle-Preserving Drug in Genetic Diseases, Raising Questions About Obesity Trial
Roche’s Genentech has halted the Phase III development of its muscle‑preserving therapy for spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD). The decision follows disappointing efficacy signals and safety concerns that emerged in late‑stage trials. The program also included an...
Appeal Finds NICE Must Reconsider Alzheimer's Drugs
NICE has agreed to revisit its June 2025 rejection of Eli Lilly’s Kisunla (donanemab) and Eisai’s Leqembi (lecanemab) for NHS reimbursement. The appeal will send the dossiers back to the appraisal committee to re‑examine clinical benefits, long‑term data, infusion costs and unpaid...
Shionogi Enrols First Patients in Esprit Trial for Pompe Disease
Shionogi announced the first patient enrollment in its global Phase II Esprit trial, evaluating the oral substrate‑reduction therapy S‑606001 in adults with late‑onset Pompe disease. The 52‑week, double‑blind, placebo‑controlled study will run across the EU, the UK and the United States,...
Mind-Altering Substances Are (Still) Falling Short in Clinical Trials
Psychedelic research has surged, but recent psilocybin trials reveal modest benefits that fail to outpace placebo. A German study with 144 treatment‑resistant depression patients found no statistically significant advantage for high‑dose psilocybin. An open‑label review of 24 trials concluded psychedelics...
LivaNova’s Aura6000 System Secures the US FDA Premarket Approval to Treat Obstructive Sleep Apnea (OSA)
LivaNova received FDA Premarket Approval for its aura6000 neurostimulation system, targeting adults with moderate‑to‑severe obstructive sleep apnea (OSA) who cannot use or have failed first‑line therapies. The approval is based on the OSPREY randomized controlled trial, which showed a 65%...
STAT+: Novartis Picks up Experimental Breast Cancer Therapy for $2B
Novartis announced the acquisition of experimental breast‑cancer drug SNV4818 from Synnovation Therapeutics for a $2 billion upfront payment, with up to $1 billion in milestone‑based earn‑outs. The oral agent is in a Phase 1/2 study targeting mutant PI3Kα in HR‑positive, HER2‑negative tumors while...
Modifying T Cell Receptor Improves Targeted Cancer Therapy
Researchers from UCLA, Stanford, Utah, and Columbia have engineered T cell receptors to strengthen catch‑bond interactions with prostate cancer antigens, improving cytotoxic function. By altering just one or two amino acids in the TCR, the modified cells exhibit longer bond...
Lab-Grown Oesophagus Restores Pigs’ Ability to Swallow
Scientists at University College London have engineered bio‑grown oesophageal segments using patient‑derived stem cells and implanted them into minipigs, restoring normal swallowing. The grafts were seeded onto decellularized scaffolds, covered with a biodegradable mesh, and integrated functional muscle, nerves, and...
Magnetic Fields Guide Lab-Grown Blood Vessels Into Precise Patterns for Drug Testing
Researchers at the Institute of Physical Chemistry (IPC PAS) and the University of Warsaw have created a magnetic‑field‑driven system that arranges endothelial‑cell‑coated microparticles into predefined lattices, prompting the growth of microvascular networks with precise architecture. By using super‑paramagnetic beads and micromagnets,...
Recursion’s Khan: AI Will Be Judged by the Medicines It Makes
Recursion Pharmaceuticals CEO Najat Khan says AI’s worth will be judged by the medicines it helps create, not by the sophistication of the tools. She emphasizes deploying AI selectively in chemistry, trial execution, and out‑of‑domain predictions to generate clinical proof...
STAT+: Trump’s Medicare Director Seeks to Rein in Expectations for TrumpRx
Chris Klomp, the HHS Medicare director, warned that President Trump’s TrumpRx drug‑discount platform is not intended for the majority of Americans with health insurance. He clarified that the program targets cash‑pay patients, leaving the 170 million commercially insured and 68 million Medicare...
BIOTECanada Welcomes the Announcement of the Pharmaceutical and Life Sciences Sector Task Force
BIOTECanada has praised the federal government’s launch of the Pharmaceutical and Life Sciences Sector Task Force, signaling a strategic push to strengthen Canada’s biotech and pharma ecosystem. The task force is tasked with reviewing investment incentives, regulatory frameworks, and market...
Could Data From 100 Million Species Help Cure Disease? One Startup Is Betting on It
Basecamp Research announced the launch of its Trillion Gene Atlas, a project to collect and model genomic data from over 100 million species, expanding known genetic diversity a hundred‑fold. Backed by $85 million in venture funding, the initiative partners with Anthropic, Ultima...
FDA Drug Safety Communication: Updated Information on 32 Mg Intravenous Ondansetron (Zofran) Dose and Pre-Mixed Ondansetron Products
The FDA announced that the 32 mg intravenous dose of ondansetron (Zofran) will be withdrawn from the market due to its association with QT‑interval prolongation and the risk of Torsades de Pointes. The agency is coordinating a voluntary recall of all...
STAT+: Novo Nordisk’s High-Dose Wegovy Approved in the U.S.
Novo Nordisk announced FDA approval of a high-dose formulation of its obesity injectable Wegovy in the United States. The approval was granted through a new FDA priority review voucher program, which Novo earned via a price‑cut deal with the Trump...
Studies Show Increased Risk of Heart Rhythm Problems with Seizure and Mental Health Medicine Lamotrigine (Lamictal) in Patients with Heart...
The FDA has issued a safety communication indicating that lamotrigine (Lamictal) may increase the risk of serious arrhythmias in patients with existing heart disease. The agency ordered in‑vitro studies after reports of abnormal ECGs, chest pain, loss of consciousness, and...
FDA Approves Linerixibat for Cholestatic Pruritus in Primary Biliary Cholangitis
The U.S. Food and Drug Administration has granted approval to GSK’s linerixibat (Lynavoy) for treating cholestatic pruritus in patients with primary biliary cholangitis (PBC). The decision rests on the GLISTEN phase‑3 trial, which demonstrated a statistically and clinically significant reduction...
Biosimilar CT-P43 Matches Ustekinumab in Treating Moderate to Severe Plaque Psoriasis
A phase‑3, double‑blind trial of over 500 patients showed the ustekinumab biosimilar CT‑P43 achieved equivalent PASI75 response at week 12 and maintained comparable PASI50/75/90 rates through week 52. Safety, adverse‑event profiles, and antidrug‑antibody incidence mirrored those of reference ustekinumab. Patients who switched...
Sarepta Plans FDA Run for Duchenne Exon Skippers Despite Confirmatory Trial Failure
Sarepta Therapeutics will submit a supplemental NDA to the FDA seeking to convert the accelerated approvals of its Duchenne exon‑skippers Amondys 45 and Vyondys 53 into traditional approvals, despite the confirmatory ESSENCE trial failing to improve motor function. The company bolsters its...
STAT+: Pharmalittle: We’re Reading About a Lilly Weight Loss Trial, TrumpRx Shortcomings, and More
Eli Lilly’s late‑stage trial of the injectable retatrutide showed a 1.9% drop in HbA1c and a 15.3% weight loss after 40 weeks, outperforming placebo and matching its blockbuster Mounjaro. The drug targets the roughly 60% of type‑2 diabetics who are also...
Excalipoint Closes $68.7M Seed Round for Cancer T-Cell Engagers
Excalipoint, a biotech focused on cancer T‑cell engagers, announced the close of a $68.7 million seed financing round. The capital, raised from leading venture firms and strategic investors, will fund the development of its bispecific antibody platform targeting solid tumors. The...
Nia Therapeutics’ Smart Neurostimulation System Receives FDA Breakthrough Device Designation to Treat Memory Loss
The U.S. Food and Drug Administration granted Breakthrough Device Designation to Nia Therapeutics’ Smart Neurostimulation System (SNS) for treating episodic memory loss in adults with moderate to severe traumatic brain injury. The fully implantable, closed‑loop system records neural activity from...
International Business Briefs | Novo Nordisk Weight-Loss Drugs’ Patent Expiry to Benefit India
This week’s corporate round‑up highlighted several pivotal moves: Novo Nordisk’s semaglutide patent lapses in India, prompting more than 40 firms to launch over 50 generic weight‑loss brands; BP agreed to sell its Gelsenkirchen refinery, targeting roughly $1 bn of operating‑cost savings;...
Quintessence Debuts First ‘Living’ Artificial Cell for CGT Bio-Separation
Quintessence Biotech introduced DACS, the first "living" artificial cell designed to streamline bio‑separation in cell and gene therapy (CGT) manufacturing. The lipid‑particle platform mimics cell size, deformability and antigen presentation, enabling a gravity‑based flotation method that replaces magnetic‑bead workflows. DACS...
STAT+: Eli Lilly’s ‘Triple-G’ Drug Leads to Significant Blood Sugar, Weight Reductions in Diabetes Trial
Eli Lilly’s investigational injectable retatrutide achieved a 1.9‑point HbA1c reduction versus 0.8 points for placebo after 40 weeks, while participants on the highest dose shed 15.3% of body weight compared with 2.6% on placebo. The weight loss was still progressing at...
AL-S Pharma Reports the P-II (AP-101-02) Trial Data on AP-101 for Amyotrophic Lateral Sclerosis (ALS)
AL‑S Pharma released Phase II (AP‑101‑02) data evaluating intravenous AP‑101 every three weeks in 73 ALS patients, including 52 with sporadic disease and 21 with SOD1 mutations. The trial met its primary safety and tolerability endpoint and demonstrated disease modification,...